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Abstract
Extracellular adherence protein (Eap) from Staphylococcus aureus
has been reported to have strong anti-inﬂammatory properties,
which make Eap a potential anti-inﬂammatory agent. However,
Eap has also been demonstrated to trigger T-cell activation and
to share structural homology with superantigens. In this study,
we focused on whether Eap fulﬁlled the deﬁnition criteria for a
superantigen. We demonstrate that T-cell activation by Eap is
dependent on both major histocompatibility complex class II and
intercellular adhesion molecule type 1, that cellular processing is
required for Eap to elicit T-cell proliferation, and that the
kinetics of proliferation resemble the proﬁle of a conventional
antigen and not that of a superantigen.
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Staphylococcus aureus is an important cause of severe bac-
terial infections in humans [1]. Extracellular adherence pro-
tein (Eap) is a virulence factor expressed by the vast
majority of S. aureus strains [2,3] and consists of four to six
repeats. Eap has many functions, including involvement in
adherence and internalization of the bacteria into eukaryotic
cells [4,5], and anti-inﬂammatory activities mediated through
binding to intercellular adhesion molecule type 1 (ICAM-1),
resulting in impairment of neutrophil and T-cell recruitment
[6,7]. Eap has also been shown to inhibit T-cell responses
[8,9]. Taken together, the functional analyses of Eap have
emphasized its anti-inﬂammatory properties, and conse-
quently, the use of Eap as a potential anti-inﬂammatory agent
has been proposed. However, Eap has furthermore been
reported to have immunostimulatory properties, including
activation of monocytes to secrete proinﬂammatory cyto-
kines [10] as well as T-cell activation [8,9]. It has also been
suggested that Eap interacts with immune cells in a superan-
tigen manner, as the three-dimensional structure of Eap
domains shows homology with the C-terminal domain of
bacterial superantigens [11]. These starkly different functional
properties of Eap prompted us to investigate the mechanism
by which Eap activates human T-cells. We focused on the
interaction between Eap and major histocompatibility com-
plex (MHC) class II molecules and whether Eap fulﬁlled the
deﬁnition criteria of a superantigen, including MHC class II
dependence and no cellular processing.
To assess MHC class II dependency, a cell proliferation
assay with human peripheral blood mononuclear cells
(PBMCs) was used essentially as described elsewhere [8].
MHC class II molecules were blocked by pre-incubation for
20 min with either anti-human leukocyte antigen (HLA)-DR
(Becton Dickinson) (20 lL/1 · 106 PBMCs) or anti-human
ICAM-1 antibodies (CD54; R&D Systems) (8 mg/L/1 ·
106 PBMCs). Anti-ICAM-1 antibodies were used because
ICAM-1 is a known receptor for Eap [6,7]. PBMCs were then
stimulated with Eap (9 mg/L) puriﬁed from S. aureus
supernatants as described previously [5]. As positive controls,
the superantigen toxic shock syndrome toxin 1 (TSST-1)
(1.25 lg/L; Sigma) and phytohaemagglutinin (PHA) (2 mg/L,
Sigma) were used. These concentrations were used in all of
the experiments in this study. Proliferative responses were
assessed after 72 h by [3H]thymidine uptake. As previously
reported [8], the proliferative response induced by Eap varied
among different donors (Fig. 1a). Importantly, the response
was almost completely abolished (98% inhibition) by pretreat-
ment of the cells with anti-MHC class II antibodies (p <0.01)
(Fig. 1a), demonstrating that MHC class II is required for an
optimal T-cell response by Eap. Also, anti-ICAM-1 antibodies
inhibited Eap-induced proliferation, but to a lesser extent
(55–82%; p <0.05) (Fig. 1a), indicating that this receptor is
also involved, most likely as a co-stimulatory molecule
[12,13]. To ensure that the responses that we measured
were Eap-speciﬁc, and not due to contaminating superanti-
gens, experiments were conducted using recombinant Eap
fragment encompassing repeats 1–3. Expression and puriﬁca-
tion of recombinant Eap repeats were performed as detailed
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elsewhere [14]. As shown in Fig. 1b, the recombinant Eap-
repeat fragment also induced T-cell proliferation, and, simi-
larly to what was found with native Eap, the response was
inhibited by 92% and 71% by pre-blocking with anti-MHC
class antibodies (p <0.01) and ICAM-1 antibodies (p <0.05),
respectively. T-cell proliferation in the presence of TSST-1,
the positive control, was inhibited by 73% and 90% by pre-
blocking with anti-MHC class antibodies (p <0.05) Fig. 1b.
To further assess MHC class II dependency, we used a
co-culture system using T-cells together with metabolically
inactive mitomycin C-treated BLS cells, untransfected or
transfected with class II alleles. BLS cells originate from a
patient with bare lymphocyte syndrome, and are deﬁcient in
class II expression. This model system has been used in several
studies of streptococcal and staphylococcal superantigen-
induced T-cell activation [15–17]. In this study, BLS cells trans-
fected with the HLA class II alleles BLS-DQ3.2 or BLS-DR4
were cultured together with T-cells puriﬁed from healthy
donors. Cells were prepared and cultured as previously
detailed [17]. Mitomycin C-treated BLS cells (1 · 108 cells/L)
were cultured with freshly isolated human T-lymphocytes
(2 · 108 cells/L) in the presence or absence of Eap, TSST-1 or
PHA. As shown in Fig. 2a, Eap failed to induce T-cell prolifera-
tion in this assay, whereas the superantigen TSST-1 induced
marked T-cell responses when presented by the HLA class II-
transfected cells. To investigate whether Eap required cellular
processing in order to activate T-cells, monocytes
(5 · 108 cells/L) were incubated for 3 h in the presence or
absence of chloroquine (0.05 mM; Sigma) prior to incubation
with freshly isolated lymphocytes (3 · 109 cells/L). The cells
were stimulated with Eap, TSST-1 or a positive control anti-
gen, CEF (cytomegalovirus, Epstein–Barr virus and inﬂuenza
virus), a control peptide pool (NIH research & reference
reagent) (2.5 mg/L). Chloroquine inhibits the acidiﬁcation of
early endosomes and lysosomes which result in an impairment
of the antigen presenting process [18]. Chloroquine treatment
resulted in a marked reduction of 40–92% in both Eap and
CEF-induced T-cell responses, whereas the TSST-1 responses
were equal in cultures with treated or untreated cells (Fig. 2b).
The lack of response by Eap in this model indicates that Eap
responses are MHC-restricted and require cellular processing
in order to induce T-cell activation, just like a conventional
antigen but unlike a superatigen.
Studies of the kinetics of T-cell activation [19] revealed
that the proliferative response of Eap and CEF could be
detected after 3 days of stimulation; the response peaked
between days 5 and 7, and declined thereafter (Fig. 2c). On
the contrary, TSST-1-induced and PHA-induced responses
peaked at day 3 and decreased rapidly thereafter.
Thus, despite Eap’s structural homology with superanti-
gens [11], Eap does not act as a superantigen, which is in
concordance with the report of Massey et al. [20]. However,
considering Eap’s potential use as an immunomodulatory
agent, it is of importance to fully elucidate its interaction
with human immune cells. Here, we demonstrate for the
ﬁrst time that Eap-induced T-cell activation is dependent on
MHC class II, and that ICAM-1 also contributes to Eap-
induced T-cell proliferation. In addition, we demonstrate that
cellular processing is required for Eap to elicit T-cell prolifer-
ation, and that the kinetics of proliferation resemble the pro-
ﬁle of a conventional antigen and not that of a superantigen.
(a)
(b)
FIG. 1. Extracellular adherence protein (Eap)-induced T-cell activa-
tion is dependent on major histocompatibility complex (MHC) class II
and intercellular adhesion molecule type 1 (ICAM-1). Peripheral blood
mononuclear cells were pre-incubated with either anti-MHC class II
antibodies or anti-ICAM-1 antibodies for 20 min prior to stimulation
with Eap (9 mg/L) (a) or recombinant Eap fragment (R13) (30 mg/L)
and toxic shock syndrome toxin 1 (TSST-1) (1.25 ng/mL) (b). T-cell
proliferation was quantiﬁed by [3H]thymidine uptake, and data are
presented as mean counts per minute (CPM). Error bars indicate stan-
dard deviation. (a) and (b) show data from, respectively, four and
three different donors. Statistical differences were determined by
two-way ANOVA, and demonstrated signiﬁcant inhibition of Eap
responses by both anti-ICAM-1 (p <0.05), anti-MHC class II (p <0.01),
and inhibition of TSST-1 by anti-MHC class II (p <0.05).
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Abstract
The molecular epidemiology of 33 Escherichia coli and 81 Klebsiel-
la pneumoniae extended-spectrum b-lactamase-producing health-
care-associated and community-acquired isolates collected in the
Helsinki district during 2000–2004 was investigated. Clonality
studies, antimicrobial susceptibility and genotyping of the isolates
were performed. Newly emerging CTX-M-producing E. coli and
blaSHV-12-producing K. pneumoniae isolates were detected. Clonal
clusters of both species persisted throughout the study period.
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The proportion of extended-spectrum b-lactamase (ESBL)-
producing Escherichia coli and Klebsiella pneumoniae has been
increasing worldwide in both community-acquired and health-
care-associated infections [1–4]. Increasing frequencies of
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